Nabriva Therapeutics PLC (NBRV)
| Market Cap | 52.18M |
| Revenue (ttm) | 5.03M |
| Net Income (ttm) | -69.48M |
| Shares Out | 34.79M |
| EPS (ttm) | -5.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $1.45 |
| Previous Close | $1.50 |
| Change ($) | -0.06 |
| Change (%) | -3.67% |
| Day's Open | 1.47 |
| Day's Range | 1.44 - 1.50 |
| Day's Volume | 488,847 |
| 52-Week Range | 1.40 - 12.00 |
- SIVEXTRO now available under Nabriva's National Drug Code
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Forget undervalued stocks, play these top-ranked stocks with rising P/E.
DUBLIN, Ireland, April 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective age...
DUBLIN, Ireland and KING OF PRUSSIA, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inno...
Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.
-Relaunched XENLETA ® (lefamulin) and SIVEXTRO ® (tedizolid phosphate) in the community with 60 sales representatives-
Nabriva Therapeutics (NBRV) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
DUBLIN, Ireland, March 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective age...
DUBLIN, Ireland and KING OF PRUSSIA, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inno...
CHICAGO, Feb. 26, 2021 /PRNewswire/ -- UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ) LARRY ENRIQUEZ v. NABRIVA ) Case No. 1:19-cv-04183-VM THERAPEUTICS PLC, et al. ) Honorable Victor Marr...
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...
Contemporary data demonstrate macrolide resistance in S. pneumoniae is 39.5 percent overall and greater than 25 percent in most regions of the country
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...
- Amen ded agreement encompasses enhanced manufacturing collaboration and regulatory support
DUBLIN, Ireland, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agen...
Nabriva Therapeutics plc's (NBRV) CEO Ted Schroeder on Q3 2020 Results - Earnings Call Transcript
-Relaunch of Xenleta® and Sivextro® commenced in late September-
DUBLIN, Ireland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agen...
-- Findings underscore potential of XENLETA as a first-in-class pleuromutilin antibiotic for the IV and oral treatment of CABP in adults, including older patients with comorbidities who are at risk of p...
-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship
Nabriva Therapeutics Plc (NBRV) CEO Ted Schroeder on Q2 2020 Results - Earnings Call Transcript
DUBLIN, Ireland, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ag...
DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ag...
Nabriva (NBRV) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.
- XENLETA represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years
-In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone
-XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc. -XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc.
Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.
DUBLIN, Ireland and KING OF PRUSSIA, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn...
Agency Cited Travel Restrictions and Inability to Conduct Onsite Inspections to Resolve Observations at Manufacturing Partner Facilities Agency Cited Travel Restrictions and Inability to Conduct Onsite ...
Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.
Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.
DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inno...
Large, contemporary, cross-sectional study highlights the urgent need for local epidemiology data to be available to inform empiric antibiotic choices that are concordant with the IDSA/ATS community-acq...
Nabriva Therapeutics Plc (NBRV) CEO Ted Schroeder on Q1 2020 Results - Earnings Call Transcript
Nabriva Therapeutics (NBRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Results support Xenleta as an empiric, short-course monotherapy replacement for respiratory fluoroquinolones for treatment of CABP Results support Xenleta as an empiric, short-course monotherapy replace...
Nabriva Therapeutics (NBRV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
DUBLIN, Ireland, April 09, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective a...
DUBLIN, Ireland, April 08, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective a...
Nabriva (NBRV) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Nabriva Therapeutics' (NBRV) CEO Ted Schroeder on Q4 2019 Results - Earnings Call Transcript
DUBLIN, Ireland, March 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective a...
DUBLIN, Ireland, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ag...
As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.
About NBRV
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI). It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well a... [Read more...]
| Industry Biotechnology | IPO Date Sep 18, 2015 |
| CEO Theodore Schroeder | Employees 72 |
| Stock Exchange NASDAQ | Ticker Symbol NBRV |
Financial Performance
In 2020, NBRV's revenue was $5.03 million, a decrease of -46.98% compared to the previous year's $9.48 million. Losses were -$69.48 million, -16.05% less than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for NBRV stock is "Buy." The 12-month stock price forecast is 6.00, which is an increase of 315.22% from the latest price.